Shirley, New York – On April 16, 2019, the global leading peptide supplier Creative Peptides announced to reorganize its diabetes-related peptides for researchers who are committed to exploring a cure for people with diabetes, a chronic disease that has made life miserable for a large proportion of the population.
The latest statistics show that 422 million people have diabetes worldwide, a drastic increase from 108 million in 1980. Diabetes mellitus can be generally classified into two main types: type 1 (or insulin-dependent) and type 2 (or non-insulin-dependent). Type 1 diabetes was caused by lack of production and secretion of insulin, probably as a result of destruction of the insulin producing pancreatic β-cells. Type 2 Diabetes, featuring insulin resistance and the body’s inability to secrete enough insulin, accounts for nearly 90% of diabetes cases.
“While insulin therapy remains the standard therapy for achieving and maintaining adequate glycemic control, especially in hospitalized patients with critical and noncritical illnesses, peptide-based diabetes treatment is leading a revolution in the treatment of diabetes due to their multi-functional properties,” says Dr. Robert Martinez, head of Creative Peptides’ synthesis businesses. “A good example is Glucagon Like Peptides (especially GLP-1), which can improve postprandial glycaemia without the hypoglycaemia and weight gain associated with aggressive insulin therapy. Moreover, it has the potential to reduce cardiovascular related morbidity.”
Till now, a couple of stable GLP-1 agonists such as liraglutide, albiglutide and dulaglutide have been approved by FDA as a new class of diabetic drugs. In addition, other peptides could also be applied in diabetes research, including: Amylins Fragments (IAPP), Chromogranin A/ Pancreastatin, Exendins Fragments, Insulin C-Peptides, Insulin-Like Growth Factors Fragments (IGF fragments), Glucagons and Glucagon Like Peptides (GLP-1 / GLP-2), Gastric Inhibitory Polypeptide and Fragments, etc.
